I assume they mean they will re-evaluate existing drugs in the clinic as well and that the review is not just strictly related to pre-clinical R&D projects.
You are correct, Teva said all its pipeline will be re-evaluate. They also intend to be more involved in managing projects they partner and share costs. All will be announced on 11/12.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.